Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent

Trial Profile

Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Arterial occlusive disorders; Vascular restenosis
  • Focus Therapeutic Use
  • Acronyms MAJESTIC
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 08 Mar 2017 Status changed to completed.
    • 22 Feb 2016 According to Boston Scientific Corporation media release, based on data of this (MAJESTIC) trial, Eluvia Stent System received CE Mark approval.
    • 28 Sep 2015 According to Boston Scientific Corporation media release, data from this trial will support global regulatory submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top